


 Cite this: *RSC Adv.*, 2021, 11, 31377

# Tetrazol-Cu(I) immobilized on nickel ferrite catalyzed green synthesis of indenopyridopyrimidine derivatives in aqueous media†

 Zahra Ghanbari and Hossein Naeimi \*

After the initial study of different protocols in the synthesis of indeno[2',1':5,6]pyrido[2,3-d]pyrimidines, herein, a new method is presented using cheaper and more accessible starting materials to produce high-efficiency products. In this protocol, the novel nanocatalyst is very effective in the progression of the reaction and increasing the efficiency. This green approach in aqueous media has several advantages as compared with other methods, such as easier work-up, very mild reaction conditions, reusability of the catalyst, and eco-friendliness. The products of this four-component condensation were evaluated using IR, <sup>1</sup>H NMR, <sup>13</sup>C NMR spectra, and C. H. N. analyses, and the catalyst structure was confirmed by FT-IR, XRD, SEM, EDX, TGA and VSM techniques.

 Received 3rd August 2021  
 Accepted 24th August 2021

DOI: 10.1039/d1ra05889d

[rsc.li/rsc-advances](http://rsc.li/rsc-advances)

## 1. Introduction

The preparation of effective biological compounds with new and simpler methods can be considered a valuable goal for organic chemists. A protocol that brings higher product efficiency despite selecting more available materials is highly desirable. In previous studies, the indenopyridopyrimidine compounds have proven their special therapeutic effects; for example, tuberculostatic,<sup>1</sup> anticonvulsants,<sup>2</sup> calcium channel antagonists,<sup>3</sup> anticancer,<sup>4</sup> antimicrobial,<sup>5</sup> antiviral,<sup>6</sup> diuretic and potassium-sparing,<sup>7</sup> antifolate,<sup>8</sup> and antiinflammatory<sup>9</sup> activities. Previous methods used to prepare this product include three-component reactions using uracil derivatives.<sup>10–13</sup> From a variety of synthetic routes, the choice of multi-component reactions (MCRs), as simple, economical, environmentally friendly, and applicable procedures, is desirable to obtain favored drug combinations. This suitable pathway easily prepares various highly functionalized heterocyclic compounds without generating many waste products that are often produced in multi-step reactions.<sup>14–27</sup> The combination of two reaction paths according to the properties of the material used can help in achieving the desired product. With this view, we have considered the preparation of indenopyridine,<sup>28</sup> pyridopyrimidines,<sup>29</sup> and pyrimidines,<sup>30</sup> in addition to the consideration of the usual preparation method for indenopyridopyrimidines.<sup>31,32</sup> With this approach, the product

is obtained using barbituric acid and ammonium acetate, instead of uracil, in a four-component reaction.

The use of copper complexes in various chemical reactions, such as alkyne–azide cycloaddition,<sup>33</sup> hydroboration reactions,<sup>34</sup> allylic alkylation reactions,<sup>35</sup> direct addition of terminal alkynes to imines,<sup>36</sup> and β-boration of α,β-unsaturated esters,<sup>37</sup> has led us to the use of these compositions as a catalyst in this reaction.

The choice of magnetic nanoparticles as a catalyst platform in chemical reactions provides a convenient separation of the heterogeneous catalyst at the end of the reaction using an external magnetic field. On the other hand, these valuable platforms have the ability to link with different functional groups for the desired purposes.<sup>38</sup>

Herein, for the first time, we report a new method for the synthesis of indenopyridopyrimidine compounds using NiFe<sub>2</sub>O<sub>4</sub>@SiO<sub>2</sub>-tetrazol-Cu(I) as the catalyst.

## 2. Experimental

### 2.1. Materials

All commercially available reagents were used without further purification and purchased from the Merck Chemical Company in high purity. All of the used solvents were purified by standard procedure.

### 2.2. Apparatus

IR spectra were obtained as KBr pellets on a PerkinElmer 781 spectrophotometer and on an impact 400 Nicolet FT-IR spectrophotometer. <sup>1</sup>H NMR and <sup>13</sup>C NMR were recorded in DMSO-*d*<sub>6</sub> solvents on a Bruker DRX-400 spectrometer with

Department of Organic Chemistry, Faculty of Chemistry, University of Kashan, Kashan, 87317, I. R. Iran. E-mail: [naeimi@kashanu.ac.ir](mailto:naeimi@kashanu.ac.ir); Fax: +98-31-55912397; Tel: +98-31-55912388

† Electronic supplementary information (ESI) available. See DOI: 10.1039/d1ra05889d



tetramethylsilane as the internal reference. The elemental analyses (C, H, N) were carried out using a Vario EL Model EA 1108 analyzer.

FE-SEM analysis was carried out using a Jeol SEM instrument (model – VEGA/TESCAN) combined with an INCA instrument for energy-dispersive X-ray spectroscopy scanning electron microscopy (EDS-SEM), with scanning electron electrode at 15 kV. The XRD patterns were recorded on an X-ray diffractometer (Bruker, D8 ADVANCE, Germany). The magnetic properties of the nanoparticles were measured using a vibrating sample magnetometer (VSM, PPMS-9T) at 300 K, Kashan University, Iran. The BANDELIN ultrasonic HD 3200 with probe model KE 76, of 6 mm diameter was used to produce ultrasonic irradiation. Thermogravimetric analysis (TGA) was performed on a Mettler TA4000 system TG-50 at a heating rate of 10 K min<sup>-1</sup> under a N<sub>2</sub> atmosphere. Melting points were obtained with a Yanagimoto micro melting point apparatus and are uncorrected. The purity determination of the substrates and reaction monitoring were accomplished by TLC on silica-gel polygram SILG/UV 254 plates (from Merck Company).

### 2.3. Catalyst preparation

**General procedure for the preparation of NiFe<sub>2</sub>O<sub>4</sub> nanoparticles.** A 3 M solution of sodium hydroxide (as the precipitating agent) was slowly mixed with salt solutions of 0.4 M ferric chloride (FeCl<sub>3</sub>·6H<sub>2</sub>O) and 0.2 M nickel chloride (NiCl<sub>2</sub>·6H<sub>2</sub>O). The pH of the solution was constantly monitored as the NaOH solution was added dropwise. The reactants were constantly stirred using a magnetic stirrer until a pH level of >12 was achieved. A specified amount of oleic acid (2–3 drops for the total reacting solution of 75 ml) was added to the solution as the surfactant. The liquid precipitate was then brought to a reaction temperature of 80 °C and stirred for 40 min. The product was cooled to room temperature and then washed twice with distilled water and ethanol to remove unwanted impurities and the excess surfactant from the prepared sample. The sample was centrifuged for 15 min at 2000 rpm and then dried overnight at above 80 °C. The acquired substance was then ground into a fine powder and then annealed for 10 h at 600 °C.<sup>39</sup>

**General procedure for preparation of the nano-NiFe<sub>2</sub>O<sub>4</sub>@SiO<sub>2</sub> core-shell.** The core-shell NiFe<sub>2</sub>O<sub>4</sub>@SiO<sub>2</sub> nanospheres were prepared by a modified Stober method;<sup>40</sup> briefly, NiFe<sub>2</sub>O<sub>4</sub> (0.5 g, 2.1 mmol) was dispersed in a mixture of ethanol (50 ml), deionized water (5 ml), and tetraethoxysilane (TEOS) (0.2 ml), followed by the addition of 5.0 ml NaOH (10% wt). This solution was stirred mechanically for 30 min at room temperature. The product, NiFe<sub>2</sub>O<sub>4</sub>@SiO<sub>2</sub>, was separated by an external magnet and was washed three times with the mixture of deionized water and ethanol and dried at 80 °C for 10 h. FT-IR (KBr pellets, cm<sup>-1</sup>): 3400 (O–H), 1023–1151 (Si–O–Si), and 590 (Fe–O).

**General procedure for the preparation of NiFe<sub>2</sub>O<sub>4</sub>@SiO<sub>2</sub>-tetrazol.** NiFe<sub>2</sub>O<sub>4</sub>@SiO<sub>2</sub> (1.0 g) was dissolved in 6 ml of pure epichlorohydrin and subjected to ultrasound for 20 minutes. The resulting mixture was stirred and refluxed at 60 °C for 24 hours. After the reaction, the mixture was washed with ethanol

and then completely dried. The resulting product was dissolved in 7 ml of dried DMF and then placed in an ultrasound bath for 20 minutes. Next, 0.6 g of sodium azide was added to the suspension and the resulting mixture was refluxed for 48 hours. After about 5 hours of the reaction, 0.29 g of phthalonitrile was added to the reaction mixture, and 0.05 g of CuI was added as a catalyst for the formation of the tetrazole ring. After the completion of the reaction, the mixture was smooth and washed with dichloromethane and ethanol, respectively, then dried in an oven at 60 °C for 12 hours.

**General procedure for the preparation of NiFe<sub>2</sub>O<sub>4</sub>@SiO<sub>2</sub>-tetrazol-Cu(i).** Here, 0.1 g of CuCl was dissolved in 5 ml of ethanol and added to the product obtained from the previous step. The resulting mixture was placed under a nitrogen atmosphere for 4 hours. Vigorous stirring helped to accelerate the reaction. Upon completion of the reaction, the product was washed with acetone and ethanol, respectively, and then dried.

**A typical procedure for the synthesis of 5-(4-chlorophenyl)-1H-indeno[2',1':5,6]pyrido[2,3-d]pyrimidine-2,4,6(3H)-trione.** A mixture of 4-chlorobenzaldehyde (1 mmol), 1,3-indanedione (1 mmol), barbituric acid (1 mmol), and ammonium acetate (1.3 mmol) was stirred in water at 95 °C for the appropriate time. The progress of the reaction was monitored by TLC. After the completion of the reaction, the corresponding solid product was obtained through simple filtering, and recrystallized from hot ethanol to afford the highly pure desired product.

The spectral information of various products, including IR, NMR, and C.H.N. analyses are given below.

*5-(4-Chlorophenyl)-1H-indeno[2',1':5,6]pyrido[2,3-d] pyrimidine-2,4,6(3H)-trione (1a).* White powder; mp: 258 °C, decompose; IR (KBr) ( $\nu_{\max}/\text{cm}^{-1}$ ): 1413, 1558 (C=C, Ar), 1634, 1693 (C=O), 3145 (C–H, sp<sup>2</sup> stretch), 3265, 3444 (NH). <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 400 MHz)  $\delta$  (ppm): 7.45–7.66 (d, 2H, *J* = 8.0 Hz), 7.51–7.52 (m, 2H), 7.67–7.75 (d, 2H), 7.80–7.82 (d, 2H, *J* = 8.0 Hz), 9.95 (s, 1H). <sup>13</sup>C NMR (100 MHz, DMSO-d<sub>6</sub>)  $\delta$  (ppm): 123.52, 125.91, 127.94, 128.68, 130.23, 132.23, 135.48, 139.16, 149.25, 162.75, 165.13, 170.00, 79.00; anal. calcd for C<sub>20</sub>H<sub>10</sub>N<sub>3</sub>O<sub>3</sub>Cl: C, 64; H, 2.67; N, 11.2%; found: C, 63.91; H, 2.70; N, 11.23%.

*5-(4-Methoxyphenyl)-1H-indeno[2',1':5,6]pyrido[2,3-d] pyrimidine-2,4,6(3H)-trione (2a).* Yellow powder; mp: 245 °C, decompose, mp (lit)<sup>41</sup> 248 °C; IR (KBr) ( $\nu_{\max}/\text{cm}^{-1}$ ): 1443, 1529 (C=C, Ar), 1665, 1750 (C=O), 2916 (C–H, sp<sup>3</sup>), 3243 (C–H, sp<sup>2</sup> stretch), 3439, 3585 (NH). <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 400 MHz)  $\delta$  (ppm): 7.02–7.04 (d, 2H, *J* = 8.0 Hz), 7.48–7.49 (m, 2H), 7.58–7.60 (d, 2H, *J* = 8.4 Hz), 7.80–7.81 (m, 2H). Anal. calcd for C<sub>21</sub>H<sub>13</sub>N<sub>3</sub>O<sub>4</sub>: C, 67.92; H, 3.50; N, 11.32%; found: C, 67.91; H, 3.47; N, 11.35%.

*5-(3-Methoxyphenyl)-1H-indeno[2',1':5,6]pyrido[2,3-d] pyrimidine-2,4,6(3H)-trione (3a).* Cream powder; mp: 231 °C, decompose; IR (KBr) ( $\nu_{\max}/\text{cm}^{-1}$ ): 1421, 1539 (C=C, Ar), 1635, 1711 (C=O), 2922 (C–H, sp<sup>3</sup>), 3179 (C–H, sp<sup>2</sup> stretch), 3342, 3467 (NH). <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 400 MHz)  $\delta$  (ppm): 7.04–7.06 (d, 2H), 7.23 (s, 1H), 7.33–7.35 (m, 2H), 7.51–7.52 (m, 2H), 7.68–7.69 (d, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-d<sub>6</sub>)  $\delta$  (ppm): 61.13, 111.67, 112.22, 118.79, 123.57, 125.91, 127.79, 129.18, 130.20, 135.46, 149.57, 161.71, 169.76, 176.16, 179.48.

*5-(3-Chlorophenyl)-1H-indeno[2',1':5,6]pyrido[2,3-d] pyrimidine-2,4,6(3H)-trione (4a).* Yellow powder; mp: 258 °C,



decompose; IR (KBr) ( $\nu_{\max}/\text{cm}^{-1}$ ): 1415, 1501 (C=C, Ar), 1645, 1715, 1736 (C=O), 3241 (C-H,  $\text{sp}^2$  stretch), 3342, 3515 (NH).  $^1\text{H}$  NMR (DMSO- $d_6$ , 400 MHz)  $\delta$  (ppm): 7.07–7.09 (d, 2H), 7.28 (s, 1H), 7.44–7.45 (m, 2H), 7.51–7.58 (m, 2H), 7.66–7.68 (d, 2H). Anal. calcd for  $\text{C}_{20}\text{H}_{10}\text{N}_3\text{O}_3\text{Cl}$ : C, 63.93; H, 2.68; N, 11.18%; found: C, 65.12; H, 2.53; N, 10.73%.

*5-(2-Fluorophenyl)-1H-indeno[2',1':5,6]pyrido[2,3-d]pyrimidine-2,4,6(3H)-trione (5a)*. Brown powder; mp: 293 °C, decompose; IR (KBr) ( $\nu_{\max}/\text{cm}^{-1}$ ): 1463, 1511 (C=C, Ar), 1608, 1722 (C=O), 3192 (C-H,  $\text{sp}^2$  stretch), 3418 (NH).  $^1\text{H}$  NMR (DMSO- $d_6$ , 400 MHz)  $\delta$  (ppm): 7.42–7.43 (d, 2H), 7.51–7.52 (m, 2H), 7.78–7.88 (m, 2H), 8.01–8.02 (d, 2H).  $^{13}\text{C}$  NMR (100 MHz, DMSO- $d_6$ )  $\delta$  (ppm): 123.52, 125.93, 127.56, 128.62, 130.26, 131.83, 135.53, 139.14, 149.23, 165.37, 174.18, 176.16. Anal. calcd for  $\text{C}_{20}\text{H}_{10}\text{N}_3\text{O}_3\text{F}$ : C, 66.85; H, 2.79; N, 11.70%; found: C, 66.90; H, 2.77; N, 11.66%.

*5-(o-Tolyl)-1H-indeno[2',1':5,6]pyrido[2,3-d]pyrimidine-2,4,6(3H)-trione (6a)*. Cream powder; mp: 282 °C, decompose; IR (KBr) ( $\nu_{\max}/\text{cm}^{-1}$ ): 1478, 1593 (C=C, Ar), 1609, 1667, 1710 (C=O), 2922 (C-H,  $\text{sp}^3$ ), 3189 (C-H,  $\text{sp}^2$  stretch), 3313, 3413 (NH).  $^1\text{H}$  NMR (DMSO- $d_6$ , 400 MHz)  $\delta$  (ppm): 2.877 (s, 3H), 7.07–7.08 (d, 2H), 7.41–7.43 (m, 2H), 7.51–7.52 (m, 2H), 7.73–7.74 (d, 2H). Anal. calcd for  $\text{C}_{21}\text{H}_{13}\text{N}_3\text{O}_3$ : C, 70.99; H, 3.66; N, 11.83%; found: C, 70.92; H, 3.69; N, 11.87%.

*5-(2,4-Dichlorophenyl)-1H-indeno[2',1':5,6]pyrido[2,3-d]pyrimidine-2,4,6(3H)-trione (7a)*. Brown powder; mp: 285 °C, decompose, mp (lit)<sup>42</sup> 289 °C; IR (KBr) ( $\nu_{\max}/\text{cm}^{-1}$ ): 1423, 1512 (C=C, Ar), 1654, 1712, 1728 (C=O), 3241 (C-H,  $\text{sp}^2$  stretch), 3341, 3415 (NH).  $^1\text{H}$  NMR (DMSO- $d_6$ , 400 MHz)  $\delta$  (ppm): 6.95 (s, 1H), 7.33–7.35 (d, 2H), 7.44–7.46 (m, 2H), 7.62–7.64 (d, 2H). Anal. calcd for  $\text{C}_{20}\text{H}_9\text{N}_3\text{O}_3\text{Cl}_2$ : C, 58.68; H, 2.20; N, 10.27%; found: C, 58.65; H, 2.17; N, 10.30%.

*5-(3-Nitrophenyl)-1H-indeno[2',1':5,6]pyrido[2,3-d]pyrimidine-2,4,6(3H)-trione (8a)*. White powder; mp: 279 °C, decompose; IR (KBr) ( $\nu_{\max}/\text{cm}^{-1}$ ): 1418, 1561 (C=C, Ar), 1369, 1512 (N=O), 1619, 1711 (C=O), 2909 (C-H,  $\text{sp}^3$ ), 3158 (C-H,  $\text{sp}^2$  stretch), 3509 (NH).  $^1\text{H}$  NMR (DMSO- $d_6$ , 400 MHz)  $\delta$  (ppm): 7.13–7.16 (m, 2H), 7.33–7.35 (d, 2H), 7.46–7.47 (d, 2H), 7.50–7.55 (m, 2H), 7.66 (s, 1H).  $^{13}\text{C}$  NMR (100 MHz, DMSO- $d_6$ )  $\delta$  (ppm): 121.27, 123.46, 125.86, 127.76, 129.46, 130.24, 134.23, 135.36, 147.63, 149.46, 168.93, 170.57, 177.77. Anal. calcd for  $\text{C}_{20}\text{H}_{10}\text{N}_4\text{O}_5$ : C, 62.18; H, 2.59; N, 18.13%; found: C, 62.11; H, 2.57; N, 18.17%.

*5-(2-Chlorophenyl)-1H-indeno[2',1':5,6]pyrido[2,3-d]pyrimidine-2,4,6(3H)-trione (9a)*. Yellow powder; mp: 228 °C, decompose; IR (KBr) ( $\nu_{\max}/\text{cm}^{-1}$ ): 1429, 1541 (C=C, Ar), 1619, 1668 (C=O), 3219 (C-H,  $\text{sp}^2$  stretch), 3336, 3412 (NH).  $^1\text{H}$  NMR (DMSO- $d_6$ , 400 MHz)  $\delta$  (ppm): 7.07–7.09 (d, 2H), 7.31–7.33 (m, 2H), 7.50–7.52 (m, 2H), 7.62–7.64 (d, 2H).  $^{13}\text{C}$  NMR (100 MHz, DMSO- $d_6$ )  $\delta$  (ppm): 123.52, 126.23, 127.63, 128.65, 130.23, 131.83, 135.19, 139.11, 149.20, 168.77, 174.16, 176.44.

*5-(4-Bromophenyl)-1H-indeno[2',1':5,6]pyrido[2,3-d]pyrimidine-2,4,6(3H)-trione (10a)*. Cream powder; mp: 242 °C, decompose; IR (KBr) ( $\nu_{\max}/\text{cm}^{-1}$ ): 1447, 1559 (C=C, Ar), 1681, 1719 (C=O), 3072 (C-H,  $\text{sp}^2$  stretch), 3235, 3527 (NH).  $^1\text{H}$  NMR (DMSO- $d_6$ , 400 MHz)  $\delta$  (ppm): 7.36–7.38 (d, 2H,  $J = 8.0$  Hz), 7.53–7.55 (m, 2H), 7.67–7.69 (d, 2H,  $J = 8.0$  Hz), 7.724 (d, 2H).  $^{13}\text{C}$  NMR (100 MHz, DMSO- $d_6$ )  $\delta$  (ppm): 120.62, 123.50, 125.88,

126.75, 127.81, 130.18, 135.46, 139.13, 141.65, 147.57, 149.23, 168.63, 174.27, 176.64. Anal. calcd for  $\text{C}_{20}\text{H}_{10}\text{N}_3\text{O}_3\text{Br}$ : C, 57.14; H, 2.38; N, 10%; found: C, 57.11; H, 2.41; N, 10.03%.

*5-(5-Methylfuran-2-yl)-1H-indeno[2',1':5,6]pyrido[2,3-d]pyrimidine-2,4,6(3H)-trione (11a)*. Red brown powder; mp: 339 °C, decompose; IR (KBr) ( $\nu_{\max}/\text{cm}^{-1}$ ): 1423, 1531 (C=C, Ar), 1631, 1733 (C=O), 2931 (C-H,  $\text{sp}^3$ ), 3130 (C-H,  $\text{sp}^2$  stretch), 3242, 3425 (NH).  $^1\text{H}$  NMR (DMSO- $d_6$ , 400 MHz)  $\delta$  (ppm): 2.73 (s, 3H), 7.45–7.47 (d, 2H), 7.67–7.70 (m, 2H), 7.84–7.87 (d, 2H). Anal. calcd for  $\text{C}_{19}\text{H}_{11}\text{N}_3\text{O}_4$ : C, 66.08; H, 3.19; N, 12.17%; found: C, 66.03; H, 3.11; N, 12.21%.


*5-(4-Nitrophenyl)-1H-indeno[2',1':5,6]pyrido[2,3-d]pyrimidine-2,4,6(3H)-trione (12a)*. Dark brown powder; mp: 343 °C, decompose, mp (lit)<sup>41</sup> 345 °C; IR (KBr) ( $\nu_{\max}/\text{cm}^{-1}$ ): 1433, 1531 (C=C, Ar), 1317, 1553 (N=O), 1621, 1739 (C=O), 3205 (C-H,  $\text{sp}^2$  stretch), 3242, 3428 (NH).  $^1\text{H}$  NMR (DMSO- $d_6$ , 400 MHz)  $\delta$  (ppm): 7.754–7.775 (d, 2H,  $J = 8.0$  Hz), 7.85–7.86 (m, 2H), 8.18–8.20 (m, 2H), 8.37–8.40 (d, 2H,  $J = 8.4$  Hz).

### 3. Results and discussion

#### 3.1. Preparation and characterization of the $\text{NiFe}_2\text{O}_4@/\text{SiO}_2$ -tetrazol-Cu(I) catalyst

The preparation of the nickel ferrite nanoparticles using the previously reported method were performed by co-precipitation of  $\text{NiCl}_2$  and  $\text{FeCl}_3$  in basic solution at 80 °C.<sup>43</sup> Scheme 1 shows the preparation method of the final catalyst. Fourier transform infrared (FT-IR) spectra, X-ray diffraction (XRD), vibrating sample magnetometer (VSM), thermo-gravimetric analysis (TGA), energy-dispersive X-ray spectroscopy (EDX) and scanning electron microscopy (SEM) techniques were utilized to confirm the catalyst structure.

The FT-IR spectra of  $\text{NiFe}_2\text{O}_4$  NPs,  $\text{NiFe}_2\text{O}_4@/\text{SiO}_2$ ,  $\text{NiFe}_2\text{O}_4@/\text{SiO}_2$ -epoxide and  $\text{NiFe}_2\text{O}_4@/\text{SiO}_2$ -tetrazol are shown in Fig. 1. The stretching modes of absorbed water appeared in the bands within the range of 3400–1600  $\text{cm}^{-1}$ . The vibrations of Fe–O and Ni–O bonds were observed at 590  $\text{cm}^{-1}$  and 433  $\text{cm}^{-1}$ , respectively. In all spectra, the absorptions of the Fe–O and Ni–O bonds give characteristic bands at 429–630  $\text{cm}^{-1}$ . The peaks at 1023, 1149, 1151  $\text{cm}^{-1}$  are related to the Si–O–Si stretching



Scheme 1 Synthesis of the  $\text{NiFe}_2\text{O}_4@/\text{SiO}_2$ -tetrazol-Cu(I).






Fig. 1 FT-IR spectra of (a) NiFe<sub>2</sub>O<sub>4</sub> NPs, (b) NiFe<sub>2</sub>O<sub>4</sub>@SiO<sub>2</sub>, (c) NiFe<sub>2</sub>O<sub>4</sub>@SiO<sub>2</sub>-epoxide, (d) NiFe<sub>2</sub>O<sub>4</sub>@SiO<sub>2</sub>-N<sub>3</sub>, and (e) NiFe<sub>2</sub>O<sub>4</sub>@SiO<sub>2</sub>-tetrazol.

vibrations in the NiFe<sub>2</sub>O<sub>4</sub>@SiO<sub>2</sub>, NiFe<sub>2</sub>O<sub>4</sub>@SiO<sub>2</sub>-epoxide and NiFe<sub>2</sub>O<sub>4</sub>@SiO<sub>2</sub>-tetrazol spectra; therefore, SiO<sub>2</sub> coated the surface of NiFe<sub>2</sub>O<sub>4</sub>.

In the NiFe<sub>2</sub>O<sub>4</sub>@SiO<sub>2</sub>-epoxide spectrum, the bending vibration and stretching vibration of CH<sub>2</sub> were attributed to the revealed bands at 1423 and 2922 cm<sup>-1</sup>, respectively. The absorption peaks at 1664, 2921 and 3096 cm<sup>-1</sup> in the FT-IR spectrum of NiFe<sub>2</sub>O<sub>4</sub>@SiO<sub>2</sub>-tetrazol are related to the stretching vibrations of C=N, C-H aliphatic, and C-H aromatic, respectively. The C=C vibrations were observed at 1481 and 1605 cm<sup>-1</sup>. The preparation of the final catalyst was proved by these described bands.

The stretching vibrations of OH, N<sub>3</sub>, and the aliphatic C-H group are shown in the FT-IR spectrum of NiFe<sub>2</sub>O<sub>4</sub>@SiO<sub>2</sub>-N<sub>3</sub> with absorption peaks at 3200–3600, 2080, and 2920 cm<sup>-1</sup> respectively. The stretching vibrations of aromatic C-H, aliphatic C-H, and C=N in the FT-IR spectrum of NiFe<sub>2</sub>O<sub>4</sub>@SiO<sub>2</sub>-tetrazol showed absorption peaks at 3096, 2921, and 1664 cm<sup>-1</sup>, respectively. In addition, C=C vibrations appeared at 1605 and 1481 cm<sup>-1</sup>.

The final product is without the nitrile groups of phthalonitrile, indicating its reaction with N<sub>3</sub> and conversion to tetrazole.<sup>38</sup>

Fig. 2 shows the powder XRD patterns of NiFe<sub>2</sub>O<sub>4</sub> NPs and NiFe<sub>2</sub>O<sub>4</sub>@SiO<sub>2</sub>-tetrazol-Cu(i). A comparison of all the characteristic peaks of NiFe<sub>2</sub>O<sub>4</sub> in the diffraction pattern with the




Fig. 2 The X-ray diffraction patterns of (a) NiFe<sub>2</sub>O<sub>4</sub>, (b) NiFe<sub>2</sub>O<sub>4</sub>@SiO<sub>2</sub>-tetrazol, and (c) NiFe<sub>2</sub>O<sub>4</sub>@SiO<sub>2</sub>-tetrazol-Cu(i).

standard XRD pattern (JCPDS file no. 03-0875) showed complete adaptability. The weaker diffraction lines in NiFe<sub>2</sub>O<sub>4</sub>@SiO<sub>2</sub>-tetrazol and NiFe<sub>2</sub>O<sub>4</sub>@SiO<sub>2</sub>-tetrazol-Cu(i) (Fig. 2b and c) are due to the NiFe<sub>2</sub>O<sub>4</sub> coating.

The average diameter of the NiFe<sub>2</sub>O<sub>4</sub> NPs and the final catalyst were calculated as 11 and 16 nm, respectively in the Debye–Scherrer equation. The morphologies and particle sizes of NiFe<sub>2</sub>O<sub>4</sub> and the final catalyst were characterized in the SEM image (Fig. 3).

The spherical morphology and uniform sizes of these nanoparticles were confirmed in this image and the average




Fig. 3 SEM images of (a) NiFe<sub>2</sub>O<sub>4</sub> NPs and (b) NiFe<sub>2</sub>O<sub>4</sub>@SiO<sub>2</sub>-tetrazol-Cu(i).



diameters of both  $\text{NiFe}_2\text{O}_4$  and  $\text{NiFe}_2\text{O}_4@\text{SiO}_2$ -tetrazol-Cu(I) were calculated to be about 8.7 nm. The EDX spectra confirmed the preparation of  $\text{NiFe}_2\text{O}_4$  and  $\text{NiFe}_2\text{O}_4@\text{SiO}_2$ -tetrazol-Cu(I) with the presence of O, Fe, and Ni, and the presence of C, N, Si and Cu, respectively, in addition to other elements in composites of these catalysts (Fig. 4).

The magnetic properties of  $\text{NiFe}_2\text{O}_4$  and  $\text{NiFe}_2\text{O}_4@\text{SiO}_2$ -tetrazol-Cu(I) nanoparticles were investigated at room temperature (Fig. 5). A vibrating sample magnetometer (VSM) reported the saturation magnetization of  $\text{NiFe}_2\text{O}_4$  NPs and the final catalyst as 16.7 and 6 emu  $\text{g}^{-1}$ , respectively. The functionalization with organic groups and coating of magnetic NPs reduced the magnetic properties. The magnetic properties of these catalysts allowed them to be separated more easily by an external magnet.

The thermal stability of the magnetic nanocatalyst was investigated by thermogravimetric analysis (TGA). This analysis confirmed the presence of different groups on the surface of the nanoparticles and their thermal stability (Fig. 6). No change in weight before 380 °C indicated a lack of solvent in the structure of the catalyst and, of course, its high thermal resistance.

The degradation of organic groups covering the  $\text{NiFe}_2\text{O}_4$  surface was observed in weight loss (40%) at 380–800 °C in the TGA curve of  $\text{NiFe}_2\text{O}_4@\text{SiO}_2$ -tetrazol-Cu(I). As a result, this catalyst is suitable for organic synthesis due to its thermal stability up to 380 °C.

### 3.2. Investigation of catalytic activity

To optimize reaction parameters and characterize the catalytic efficiency of the nanocatalyst, we considered the reaction of 4-chlorobenzaldehyde (1 mmol), 1,3-indanedione (1 mmol), barbituric acid (1 mmol), and ammonium acetate (1.3 mmol) as a model reaction (Scheme 2).

The effects of different conditions including temperature, solvent, amounts of catalyst on the reaction were determined (Tables 1–3). According to Table 1, the water solvent was shown as the most suitable solvent among the other solvents used including EtOH, MeOH,  $\text{CH}_2\text{Cl}_2$  and dimethylformamide (DMF). Accordingly, the most suitable reaction temperature that increased the reaction efficiency in the shortest reaction time was determined to be 90 °C (Table 1, entry 3).

Table 2 presents the effect of catalyst amount,  $\text{NiFe}_2\text{O}_4@\text{SiO}_2$ -tetrazol-Cu(I), on the synthesis of **1a**. Here, 0.005 g of the catalyst was recorded as the best observed result and 94% of the product was obtained from the application of this amount of




Fig. 4 EDX spectrum of (a)  $\text{NiFe}_2\text{O}_4$  NPs and (b)  $\text{NiFe}_2\text{O}_4@\text{SiO}_2$ -tetrazol-Cu(I).




Fig. 5 Magnetization versus applied field for (a)  $\text{NiFe}_2\text{O}_4$  NPs and (b)  $\text{NiFe}_2\text{O}_4@\text{SiO}_2$ -tetrazol-Cu(I).

catalyst in the reaction under reflux conditions at two hours (Table 2, entry 8). The substrates were placed in the reaction vessel without the catalyst under the defined conditions; after eight hours no product was obtained (Table 2, entry 11).

Each of the substituted aryl derivatives in the optimal conditions specified in the previous step presented a different yield of the product (Table 3). The high efficiency of the product and short reaction time have given a special advantage to electron-withdrawing substituents, especially the 4-nitro group with a 96% yield. However, the highest reaction time and the lowest yield were obtained for the 2-methyl group. Electron donation and the steric hindrance of the *ortho* position are two effective factors in generating this result. The structures of all products were confirmed by infrared (IR),  $^1\text{H}$  NMR, and C.H.N analysis.

### 3.3. Proposed reaction mechanism

The mechanism shown in Scheme 3 strongly confirms the above observations and the catalyst effects. The effect of the metal complex catalyst on the carbonyl oxygen of the aldehyde provides a good electrophilic center for the nucleophilic attack of 1,3-indanedione. Thus, the intermediate **I** is formed from a Knoevenagel condensation. Another condensation between barbituric acid and ammonium acetate yielded the





Fig. 6 TGA curve of (a)  $\text{NiFe}_2\text{O}_4$  NPs and (b)  $\text{NiFe}_2\text{O}_4@\text{SiO}_2$ -tetrazol-Cu(I).





Scheme 2 Synthesis of indenopyridopyrimidine.

Table 1 Optimization of the solvent and temperature in model reaction<sup>a</sup>

Entry	Solvent	Temperature (°C)	Yield <sup>b</sup> (%)
1	Water	50	60
2	Water	80	89
3	Water	90	92
4	Ethanol	50	55
5	Ethanol	60	79
6	Ethanol	70	85
7	Methanol	40	45
8	Methanol	50	67
9	Methanol	70	70

<sup>a</sup> Reaction conditions: 4-chlorobenzaldehyde (1 mmol), 1,3-indanedione (1 mmol), barbituric acid (1 mmol), and ammonium acetate (1.3 mmol). <sup>b</sup> Isolated yields.

Table 2 Different amounts of catalyst in the model reaction<sup>a</sup>

Entry	Catalyst (mol% or g)	Time (h)	Yield <sup>b</sup> (%)
1	NiFe <sub>2</sub> O <sub>4</sub> NPs (3%)	3.5	80
2	NiFe <sub>2</sub> O <sub>4</sub> NPs (2%)	3	85
3	NiFe <sub>2</sub> O <sub>4</sub> NPs (1%)	2.5	90
4	NiFe <sub>2</sub> O <sub>4</sub> NPs (0.5%)	2	89
5	NiFe <sub>2</sub> O <sub>4</sub> NPs (0.3%)	3	83
6	NiFe <sub>2</sub> O <sub>4</sub> @SiO <sub>2</sub> -tetrazol-Cu(I) (0.002 g)	2	80
7	NiFe <sub>2</sub> O <sub>4</sub> @SiO <sub>2</sub> -tetrazol-Cu(I) (0.001 g)	2.5	87
8	NiFe <sub>2</sub> O <sub>4</sub> @SiO <sub>2</sub> -tetrazol-Cu(I) (0.005 g)	2	94
9	NiFe <sub>2</sub> O <sub>4</sub> @SiO <sub>2</sub> -tetrazol-Cu(I) (0.0003 g)	3.5	79
10	NiFe <sub>2</sub> O <sub>4</sub> @SiO <sub>2</sub> -tetrazol-Cu(I) (0.0002 g)	4	75
11	Without catalyst	8	0

<sup>a</sup> Reaction conditions: 4-chlorobenzaldehyde (1 mmol), 1,3-indanedione (1 mmol), barbituric acid (1 mmol), and ammonium acetate (1.3 mmol). <sup>b</sup> Yields.

intermediate **II** (enamine). The interaction of two existing fragments gave the intermediate **III**. The desired product was achieved through intramolecular nucleophilic addition followed by the removal of water. According to observations, the role of catalytic activation in this process is very important.

### 3.4. Reusability of catalyst


The importance of the recyclability of heterogeneous catalysts in improving their performance in other reactions requires

Table 3 Synthesis of indenopyridopyrimidines (**1a–12a**) from various aromatic aldehydes under optimum conditions (h: reaction time, %: product efficiency)

94%, 2h <b>1a</b>	71%, 4h <b>2a</b>	79%, 3h <b>3a</b>
83%, 3h <b>4a</b>	90%, 2.5 h <b>5a</b>	63%, 4h <b>6a</b>
91%, 2h <b>7a</b>	84%, 3h <b>8a</b>	91%, 2.5h <b>9a</b>
90%, 2.5h <b>10a</b>	90%, 2.5h <b>11a</b>	96%, 2h <b>12a</b>

a study on their sustainability. For this purpose, the catalyst was extracted from the reaction mixture using an external magnet and after rinsing several times with water and ethanol, it was dried at 80 °C in an oven for 9 h and reused in subsequent





Scheme 3 The proposed reaction mechanism for the formation of **1a** (●:  $\text{NiFe}_2\text{O}_4@/\text{SiO}_2\text{-tetrazol-Cu(I)}$ ).




Fig. 7 Recyclability of  $\text{NiFe}_2\text{O}_4@/\text{SiO}_2\text{-tetrazol-Cu(I)}$  for the synthesis of **1a**.

reactions. Satisfaction of catalyst activity after being reused six times proves its recyclability and stability in repeated reactions (Fig. 7).

## 4. Conclusions

We have synthesized indenopyridopyrimidine compounds by using a designed catalyst to provide a green, efficient and convenient process with easy access to starting materials. This procedure provides a new synthetic route that uses readily available compounds and is low-cost with a short reaction time and a high percentage yield of the desired products. From another standpoint, we designed a heterogeneous catalyst covered with functional groups, which affects the progression of the reaction, is reusable in other reactions and provides a credible approach to the use of this pathway. FT-IR spectroscopy, SEM, TGA, EDX analysis, and XRD confirmed the synthesis of the catalyst.

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

The authors are grateful to University of Kashan for supporting this work by Grant number 159148/85.

## Notes and references

- I. D. Bystryakova, I. A. Burova, G. M. Chelysheva, S. V. Zhilinkova, N. M. Smirnova and T. S. Safonova, *Khim.-Farm. Zh.*, 1991, **25**, 31–35.
- A. B. Deyanov, R. K. Niyazov, F. Y. Nazmetdinov, B. Y. Syropyatov, V. E. Kolla and M. E. Konshin, *Khim.-Farm. Zh.*, 1991, **25**, 26.
- A. Pastor, R. Alajarin, J. J. Vaquero, J. Alvarez-Builla, M. Fau de Casa-Juana, C. Sunkel, J. G. Priego, I. Fonseca and J. Sanz-Aparicio, *Tetrahedron*, 1994, **50**, 8085–8098.
- N. M. Evdokimov, S. V. Slambrouck, P. Heffeter, L. Tu, B. L. Calve, D. Lamoral-Theys, C. J. Hooten, P. Y. Uglinskii, S. Rogelj, R. Kiss, W. F. A. Steelant, W. Berger, J. J. Yang, C. G. Bologna, A. Kornienko and I. V. Magedov, *J. Med. Chem.*, 2011, **54**, 2012–2021.
- A. Gangjee, A. Vasudevan, F. Queener and R. J. Kisliuk, *Med. Chem.*, 1996, **39**, 1438.
- M. Manpadi, P. Y. Uglinskii, S. K. Rastogi, K. M. Cotter, Y. C. Wong, L. A. Anderson, A. J. Ortega, S. V. Slambrouck, W. F. A. Steelant, S. Rogelj, P. Tongwa, M. Yu. Antipin, I. V. Magedov and A. Kornienko, *Org. Biomol. Chem.*, 2007, **5**, 3865–3872.
- I. O. Donkor, C. L. Klein, L. Liang, N. Zhu, E. Bradley and A. M. Clark, *J. Pharm. Sci.*, 1995, **84**, 661–664.
- M. N. Nasr and M. Gineinah, *M. Arch. Pharm.*, 2002, **6**, 289.
- A. Monge, V. Martinez-Merino, C. Sanmartin, F. J. Fernandez, M. C. Ochoa, C. Berllver, P. Artigas and E. Fernandez-Alvarez, *J. Med. Chem.*, 1989, **24**, 209–216.
- A. Rosowsky, C. E. Mota and S. F. Queener, *J. Heterocycl. Chem.*, 1995, **32**, 335–340.
- V. E. Kolla, A. B. Deyanov, F. Y. Nazmetdinov, Z. N. Kashina and L. P. Drovosekova, *Pharmaceut. Chem. J.*, 1993, **27**, 635–636.
- M. Ghashang, S. Guhanathan and S. Sheik Mansoor, *Res. Chem. Intermed.*, 2017, **43**(12), 7257–7276.
- J. M. Khurana, A. Chaudhary, B. Nand and A. Lumb, *Tetrahedron Lett.*, 2012, **53**, 3018–3022.
- S. Abdolmohammadi, S. Balalaie and M. Barari, *Comb. Chem. High Throughput Screening*, 2013, **16**, 150.
- N. M. Evdokimov, S. V. Slambrouck, P. Heffeter, L. Tu, B. L. Calvé, D. Lamoral-Theys, C. J. Hooten, P. Y. Uglinskii, S. Rogelj, R. Kiss, W. F. A. Steelant, W. Berger, J. J. Yang, C. G. Bologna, A. Kornienko and I. V. Magedov, *J. Med. Chem.*, 2011, **54**, 2012.
- A. Bazar and M. Ghashang, *React. Kinet. Mech. Catal.*, 2016, **118**, 463.
- M. Ghashang, *Res. Chem. Intermed.*, 2016, **42**, 4191–4205.
- M. Dehbashi, M. Aliahmad, M. R. Mohammad Shafiee and M. Ghashang, *Synth. React. Inorg., Met.-Org., Nano-Met. Chem.*, 2013, **43**, 1301.
- A. Domling and I. Ugi, *Angew. Chem., Int. Ed.*, 2000, **39**, 3168.



- 20 M. N. Elinson, A. I. Ilovaisky, V. M. Merkulova, F. Barba and B. Batanero, *Tetrahedron*, 2013, **69**, 7125–7130.
- 21 N. Chatani and T. Hanafusa, *Bull. Chem. Soc. Jpn.*, 1990, **63**, 2134–2135.
- 22 T. B. Poulsen, C. Alemparte and K. A. Jørgensen, *J. Am. Chem. Soc.*, 2005, **127**, 11614.
- 23 A. K. El-Shafei, A. A. Sultan, A. M. Soliman and E. A. Ahmed, *Synth. Commun.*, 1995, **25**, 3211–3217.
- 24 B. Sreedhar, A. S. Kumar and P. S. Reddy, *Tetrahedron Lett.*, 2010, **51**, 1891–1895.
- 25 B. V. Subba Reddy, A. Siva Krishna, A. V. Ganesh and G. G. K. S. Narayana Kumar, *Tetrahedron Lett.*, 2011, **52**, 3342–3344.
- 26 I. Ugi and A. Domling, *Endeavour*, 1994, **18**, 115.
- 27 S. Heck and A. Domling, *Synlett*, 2000, 424.
- 28 P. K. Tapaswi and C. Mukhopadhyay, *ARKIVOC*, 2011, **10**, 287–298.
- 29 I. O. Donkor, C. L. Klein, L. Liang, N. Zhu, E. Bradley and A. M. Clark, *J. Pharm. Sci.*, 1995, **84**, 661–664.
- 30 H. Naeimi and A. Didar, *Ultrason. Sonochem.*, 2017, **34**, 889–895.
- 31 D.-Q. Shi, Y. Li and H.-Y. Wang, *J. Heterocycl. Chem.*, 2012, **49**, 1086–1090.
- 32 G. I. Shakibaei, A. Feiz, H. R. Khavasi, A. A. Soorki and A. Bazgir, *ACS Comb. Sci.*, 2011, **13**(1), 96–99.
- 33 M. T. Ramírez-Palma, J. Segura-Arzate, G. López-Téllez and E. Cuevas-Yañez, *J. Chem.*, 2016, 853–860.
- 34 Y. Lee and A. H. Hoveyda, *J. Am. Chem. Soc.*, 2009, **131**(9), 3160–3161.
- 35 J. J. Van Veldhuizen, J. E. Campbell, R. E. Giudici and A. H. Hoveyda, *J. Am. Chem. Soc.*, 2005, **127**(18), 6877–6882.
- 36 C. Wei and C. J. Li, *J. Am. Chem. Soc.*, 2002, **124**(20), 5638–5639.
- 37 V. Lillo, A. Prieto, A. Bonet, M. Mar Díaz-Requejo, J. Ramírez, P. J. Pérez and E. Fernández, *Organometallics*, 2009, **28**(2), 659–662.
- 38 R. Ghosh, L. Pradhan, Y. P. Devi, S. Meena, R. Tewari, A. Kumar, S. Sharma, N. Gajbhiye, R. Vatsa and B. N. Pandey, *J. Mater. Chem.*, 2011, **21**, 13388–13398.
- 39 K. Maaz, S. Karim, A. Mumtaz, S. K. Hasanain, J. Liu and J. L. Duan, *J. Magn. Mater.*, 2009, **321**, 1838.
- 40 Y. H. Deng, D. W. Qi, C. H. Deng, X. M. Zhang and D. Y. Zhao, *J. Am. Chem. Soc.*, 2008, **130**, 28–29.
- 41 H. R. Dehghanpour, M. H. Mosslemin and R. Mohebat, *J. Chem. Res.*, 2018, **42**(1), 35–39.
- 42 N. M. Evdokimov, S. V. Slambrouck, P. Heffeter, L. Tu, B. L. Calvé, D. Lamoral-Theys, C. J. Hooten, P. Y. Uglinskii, S. R. Kiss, W. F. A. Steelant, W. Berger, J. J. Yang, C. G. Bologa, A. Kornienko and I. V. Magedov, *J. Med. Chem.*, 2011, **54**(7), 2012–2021.
- 43 A. Elhampour, F. Nemati, H. T. Nahzomi and V. Mohagheghi, *Res. Chem. Intermed.*, 2017, **43**, 6737–6761.

